LO MINASTRIN
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

LO MINASTRIN Trademark

Serial Number: 87263903

LO MINASTRIN is a trademark filed by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED on December 9, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (253 trademarks)

CLONSHAUGH BUSINESS & TECHNOLOGY PARK
COOLOCK, DUBLIN 17 , IE

Entity Type: 77

Trademark Details

Filing Date

December 9, 2016

Registration Date

Not Registered

Published for Opposition

August 8, 2017

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 9, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 9, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 27, 2020 EXRA
SOU EXTENSION 5 GRANTED
Mar 26, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 26, 2020 AITU
SOU EXTENSION 5 FILED
Mar 24, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Mar 24, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 26, 2019 EXRA
SOU EXTENSION 4 GRANTED
Sep 24, 2019 EX4G
SOU EXTENSION 4 FILED
Sep 24, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 24, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 14, 2019 EXRA
SOU EXTENSION 3 GRANTED
Mar 12, 2019 EX3G
SOU EXTENSION 3 FILED
Mar 12, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 12, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 29, 2018 EXRA
SOU EXTENSION 2 GRANTED
Sep 27, 2018 EX2G
SOU EXTENSION 2 FILED
Sep 27, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 27, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 2, 2018 EXRA
SOU EXTENSION 1 GRANTED
Feb 28, 2018 EX1G
SOU EXTENSION 1 FILED
Feb 28, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 28, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 3, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 8, 2017 NPUB
PUBLISHED FOR OPPOSITION
Aug 8, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 19, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 29, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 9, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 8, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 8, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 13, 2017 GNRN
NON-FINAL ACTION E-MAILED
Mar 13, 2017 GNRT
NON-FINAL ACTION WRITTEN
Mar 13, 2017 CNRT
ASSIGNED TO EXAMINER
Mar 13, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 14, 2016 NWOS
NEW APPLICATION ENTERED
Dec 13, 2016 NWAP